Chronic Total Occlusion PCI Is Getting Safer -- At Least Until the Pandemic
(MedPage Today) -- ATLANTA -- Percutaneous coronary intervention for chronic total occlusion (CTO PCI) has improved in success rates, but the pandemic might have impacted complication rates, a registry study showed. Technical and procedural... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 21, 2022 Category: Cardiology Source Type: news

Addition of Icosapent Ethyl Cuts CV Risk in Patients With Prior PCI
THURSDAY, March 24, 2022 -- The risk for cardiovascular events is reduced in statin-treated patients with elevated triglycerides and a history of percutaneous coronary intervention (PCI) who receive icosapent ethyl, according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 24, 2022 Category: Pharmaceuticals Source Type: news

Multivessel traumatic coronary artery dissection after a motor vehicle accident with successful percutaneous coronary intervention - Pandey Y, Owen B, Birnbaum G, Tabbaa R, Hamzeh I, Lakkis N, Kayani W.
We report a case of acute left anterior descending and right coronary artery dissections after a motor vehicle accident. The musculoskeletal injuries obscured the cardiac symptom... (Source: SafetyLit)
Source: SafetyLit - July 30, 2021 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Medtronic Launches Newest-Generation Drug Coated Balloon Catheter in Europe for Treatment of Coronary Artery Disease
Medtronic Prevail DCB™ Designed to Treat Complex Lesions with Superior Deliverability, Rapid Absorption of Paclitaxel DUBLIN, July 26, 2021 -- (Healthcare Sales & Marketing Network) -- Medtronic plc (NYSE: MDT), the global leader in medical technology,... Devices, Interventional, Cardiology, Regulatory Medtronic, Prevail DCB, percutaneous coronary intervention (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 26, 2021 Category: Pharmaceuticals Source Type: news

Impact of Age Examined for Ticagrelor Monotherapy After PCI
WEDNESDAY, July 7, 2021 -- For patients undergoing percutaneous coronary intervention, ticagrelor monotherapy following three months of dual antiplatelet therapy significantly reduces clinically relevant bleeding compared with ticagrelor with... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 7, 2021 Category: Pharmaceuticals Source Type: news

Ticagrelor, Prasugrel Compared in ACS Treated With PCI
TUESDAY, July 6, 2021 -- For patients presenting with acute coronary syndrome (ACS) who undergo percutaneous coronary intervention (PCI), a postrandomization subgroup analysis suggests that a prasugrel-based strategy is superior to a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 6, 2021 Category: Pharmaceuticals Source Type: news

Preventable Risk Factors Widespread in Patients Undergoing Angioplasty
WEDNESDAY, June 23, 2021 -- Modifiable risk factors remain widely prevalent among patients undergoing their first percutaneous coronary intervention (PCI), according to a study published online June 9 in PLOS ONE. Zoya Gurm, from the Wayne State... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 23, 2021 Category: Pharmaceuticals Source Type: news

Stents or bypass surgery more effective for stable patients with high-risk cardiac anatomy
(University of Alberta Faculty of Medicine& Dentistry) A study by University of Alberta cardiologists at the Canadian VIGOUR Centre shows that a particular group of patients with stable ischemic heart disease have better outcomes with percutaneous coronary intervention (also called angioplasty with stent) or coronary artery bypass surgery and medication, versus conservative management with medication alone. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 18, 2021 Category: International Medicine & Public Health Source Type: news

Primary PCI Use Down for Cancer Patients With STEMI
WEDNESDAY, Feb. 17, 2021 -- Patients with active cancer who have ST-elevation myocardial infarction (STEMI) receive primary percutaneous coronary intervention (pPCI) less often, but they have significantly lower rates of in-hospital all-cause... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 17, 2021 Category: Pharmaceuticals Source Type: news

Cancer patients not receiving life-saving heart attack treatment
(European Society of Cardiology) Emergency heart attack treatment is effective in patients with cancer, yet many do not receive it. That's the finding of a study published on World Cancer Day in European Heart Journal - Acute Cardiovascular Care, a journal of the European Society of Cardiology (ESC).1 This was the first study to compare the rates of primary percutaneous coronary intervention (PCI) in heart attack patients with and without cancer, and to examine the comparative effectiveness and safety of treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 3, 2021 Category: Cancer & Oncology Source Type: news

Symptom-to-Balloon Time Linked to Infarct Size in STEMI
THURSDAY, Jan. 14, 2021 -- For patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI), symptom-to-balloon time (SBT), but not door-to-balloon time (DBT), is associated with... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 14, 2021 Category: Pharmaceuticals Source Type: news

Physician-Level PCI Mortality Data May Be Misleading Physician-Level PCI Mortality Data May Be Misleading
Percutaneous coronary intervention mortality data do not adequately reflect the quality of care delivered by cardiologists who perform this procedure at multiple centers, researchers report.Medscape Medical News (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - January 4, 2021 Category: Intensive Care Tags: Cardiology News Source Type: news

Clopidogrel Bests Ticagrelor for Elective PCI Clopidogrel Bests Ticagrelor for Elective PCI
Ticagrelor failed to unseat clopidogrel as the guideline-recommended P2Y12 inhibitor of choice in patients undergoing elective percutaneous coronary intervention for stable CAD in the randomized ALPHEUS trial.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 15, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

Results from the TARGET FFR study reported at TCT Connect
(Cardiovascular Research Foundation) Results from the randomized controlled TARGET FFR trial show that while a physiology-guided percutaneous coronary intervention (PCI) optimization strategy did not achieve a significant increase in the proportion of patients with final FFR ?0.90, it reduced the proportion of patients with a residual FFR ?0.80 following PCI. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 16, 2020 Category: International Medicine & Public Health Source Type: news

Medtronic Resolute Onyx ™ Drug Eluting Stent (DES) First to Receive One-Month DAPT Labeling in the U.S. with Expanded Indication for High Bleeding Risk Patients
Medtronic plc (NYSE:MDT) today announced it has received U.S. Food and Drug Administration (FDA) approval for new one-month of dual-antiplatelet therapy (DAPT) labeling with an expanded indication for high bleeding risk (HBR) patients implanted with the Resolute Onyx ™ DES. The Resolute Onyx DES is the first-and-only DES in the U.S. that has been proven safe and effective utilizing a one-month regimen of DAPT – the combination of aspirin and an anti-clotting medication – following a percutaneous coronary intervention (PCI) in patients at high bleeding risk . (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - October 1, 2020 Category: Cardiology Source Type: news